Gregory Piazza on The Effect of Enduring Risk Factors in Provoked VTE
Gregory Piazza, Director of the Vascular Medicine Section at Brigham and Women’s Hospital, shared on LinkedIn:
”What impact do the type and number of enduring risk factors have on the risk of recurrent venous thromboembolism in patients with an initial provoked event?
A subanalysis of our HI-PRO randomized controlled trials demonstrates just how important recognition of enduring risk is for shared decision making on extended secondary prevention.”
Read the full article here.
Article: Impact of enduring risk factors on efficacy and safety of extended anticoagulation for provoked venous thromboembolism: Post-hoc analysis of the HI-PRO trial
Authors: Mariana Pfeferman, Sina Rashedi, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, Samuel Z. Goldhaber, Behnood Bikdeli, Gregory Piazza on behalf of the HI-PRO Trial Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition